The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
about
B cells in chronic graft-versus-host diseaseTargeting the Fc receptor in autoimmune diseaseTargets for Ibrutinib Beyond B Cell MalignanciesExploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics SimulationTargeting Btk/Etk of prostate cancer cells by a novel dual inhibitorSafety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participantsAdvances in kinase inhibition: treating rheumatic diseases and beyond.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyEgress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Back to the future: oral targeted therapy for RA and other autoimmune diseases.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaTargeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesB-cell selection and the development of autoantibodies.Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsAnalysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.Novel Bruton's tyrosine kinase inhibitors currently in development.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisModulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells.TEC and MAPK Kinase Signalling Pathways in T helper (TH) cell Development, TH2 Differentiation and Allergic Asthma.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesCurrent understanding of tyrosine kinase BMX in inflammation and its inhibitors.Management of thrombotic thrombocytopenic purpura: current perspectivesRole of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseHumoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE studyPCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.Tec family kinases in inflammation and disease.Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.Pathways for bone loss in inflammatory disease.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
P2860
Q26861706-8B8A3EBC-2C6C-4AAA-A96C-59C773A14D9CQ27002843-D5DAF9C0-A7F0-4514-9AFD-7C1639770AA2Q28087772-ED0E2FC5-6C33-476D-A28A-4188F19F60D4Q28552585-3DFC1C93-F857-44CA-A96D-270A2DFD8EC7Q30661625-0706FB6B-79B0-45F7-B16D-39B077588CB2Q33653945-FAB717D2-2F4D-4F68-A1AF-C4A12E31B6F4Q33930795-E05C368E-2473-42F2-93EE-37F57865E237Q34020276-1595D54A-7F8A-414C-9FD9-C5E67A897813Q34037828-9BD6A93D-E0BD-4F84-8983-5F09EE96932FQ34039406-7A6775B3-6E8C-4335-B664-2B2ADD998488Q34213332-73B06FDE-25A4-4DFF-8313-9A2CFE6AB425Q34722000-993B7D82-EAB4-4208-97D7-142711CACAB9Q35140097-3AC739AD-F210-414B-BDEC-4AFD247DE639Q35181271-B4086602-7123-4EED-9617-6E311E9BB739Q36206430-40617C5C-4EC2-4668-B827-13502E403459Q36334833-96E3B7F2-B38A-4447-99EF-6519C63C9536Q36504635-1336E254-AD3E-4E6D-A5A2-6FA96CA4765DQ36544565-5EE15550-A38B-4E86-BF13-8372EED097C3Q36548443-19D19612-A308-4B5D-904E-5BA04748A28BQ36597341-06538E5C-74C9-48A0-8359-9F4D077D4430Q36673755-FE11D923-3A7D-4010-A9A0-85708054BBBDQ36810546-39131BD1-AED2-4543-96AA-A33DA8116229Q36907698-9C44453A-9C77-4093-8881-3BC18FF00FD1Q36918248-2D62DDAB-E082-495B-B7DD-5FB203860F4AQ36994373-01964D4F-2A78-47A4-B42C-D804D13CD913Q37078972-C9944C3E-3AA6-4FE3-8AA5-5411C594C22BQ37219806-5F6C5258-281A-410C-B437-70B2226002BAQ37226729-12884FD3-DECF-4057-BA73-3B560F16ECEAQ37233499-754AB07D-FA4B-4D1E-8B7F-9A723DC82F0DQ37577785-07212DBE-ED91-4087-864D-E9E2246ADAF8Q37678085-E5114929-74A8-4D0B-93CB-C361762B33C1Q37709461-50758498-06E8-4F03-9EFB-4D9DC96A41A4Q37744817-C0F7EE50-B0F7-47D2-8E2F-910E436D7A55Q37980900-D168240D-F74A-4560-B009-1ABE6CF3AC66Q37997073-168BE5F3-0E2B-4E04-8A44-BF12CCEA24ADQ37997075-5C254BF9-A850-4916-8B4D-EAD32115C970Q38004935-CB74188E-8A01-4E55-9B53-2E9E89AA83E5Q38011765-32BFA6FE-6545-405F-8390-98F2EE4A5F7BQ38083077-D99B6B24-E115-4DD1-9534-7136B2922FFFQ38124120-84666907-83C9-4837-8EF1-D039082F3EBD
P2860
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@ast
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en-gb
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@nl
type
label
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@ast
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en-gb
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@nl
prefLabel
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@ast
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en-gb
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@nl
P2093
P2860
P356
P1476
The Bruton tyrosine kinase inh ...... ion of multiple effector cells
@en
P2093
Betty Y Chang
Jeremy Sokolove
Joseph J Buggy
Michelle Francesco
Min Mei Huang
Padmaja Magadala
William H Robinson
P2860
P2888
P356
10.1186/AR3400
P407
P577
2011-01-01T00:00:00Z
P5875
P6179
1040567605